Insilico's AI-designed cancer drug shows 40% response rate in mesothelioma

Oct 26, 2026 · Issue 13 · 2 sources, 2 articles

Insilico Medicine reported a 40% response rate in the high-dose mesothelioma group for its AI-designed cancer drug. The result was published on 26 October.

Who is affected and how

pharmaceuticals

Clinical efficacy data on AI-designed molecules serve as evidence when assessing AI-driven pipelines.

Sources

• Insilico Medicine's AI-Designed Cancer Drug Shows Promise: Mesothelioma High-Dose Group Response Rate Hits 40%biggo finance · Oct 26, 2026
• Insilico Medicine’s AI Drug Posts 40% Response Rate in Treatment-Resistant Mesotheliomatech times · Oct 27, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.